Thursday, 26 May 2022

Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection

Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection
Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection

Zydus Lifesciences Ltd has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials (USRLD: Alimta). Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma.

admin Thu, 05/26/2022 - 15:16

source https://www.pharmatutor.org/content/may-2022/zydus-lifesciences-receives-final-approval-from-usfda-for-pemetrexed-for-injection

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...